Teva's migraine prophylaxis drug now approved in Europe

1 April 2019

Following a positive European Medicines Agency advisory recommendation in February, the European Commission has granted the Marketing Authorization for Ajovy (fremanezumab) 225mg solution for injection in pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.

Although Teva Pharmaceutical Industries’ (NYSE: TEVA) Ajovy was not the first of its class to be approved, according to Teva it is the first and only anti-CGRP drug approved in the European Union and the USA that is designed for the prevention of migraine that offers both quarterly and monthly dosing options for the phrophylactic treatment of migraine.

The EC decision is applicable to all 28 EU member states plus Iceland, Norway and Liechtenstein after transposition into legally binding acts in these countries. Ajovy received US Food and Drug Administration approval for the preventive treatment of migraine in adults on September 14, 2018. Additional regulatory filings are underway with other health authorities worldwide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK